Stem cell transplantation for neuroblastoma.

Area of Science:

• Pediatric Oncology
• Hematology
• Stem Cell Transplantation

Background:

• High-risk neuroblastoma presents a significant challenge in pediatric oncology due to its poor prognosis.
• Therapeutic advancements, particularly dose intensification, have gradually improved survival rates.
• Autologous hematopoietic stem cells (HSCs) enable dose escalation beyond traditional marrow tolerance.

Purpose of the Study:

• To review the evolution and impact of hematopoietic stem cell transplantation (HSCT) in treating high-risk neuroblastoma.
• To highlight the benefits of dose-intensified chemotherapy supported by HSCT.
• To discuss recent advancements in HSCT and supportive care for improved patient outcomes.

Main Methods:

• Review of therapeutic strategies for high-risk neuroblastoma.
• Analysis of the role of autologous hematopoietic stem cell rescue.
• Evaluation of newer approaches including peripheral blood stem cells (PBSC) and supportive care.

Main Results:

• Dose-intensified chemotherapy with autologous HSCT has led to improved survival.
• Transition to PBSC has further enhanced survival rates.
• Improvements in supportive care have decreased treatment-related mortality.

Conclusions:

• Hematopoietic stem cell transplantation is a critical component in improving outcomes for high-risk neuroblastoma.
• Ongoing research into experimental HSCT approaches holds promise for further advances.
• The integration of novel HSCT techniques and supportive care is key to overcoming the challenges of this disease.